文献速递创伤与烧伤心脑血管急症重症综合管理与镇静镇痛

血小板功能检测对接受抗血小板治疗的创伤性脑损伤患者的预测价值

Predictive value of platelet function assays in traumatic brain injury patients on antiplatelet therapy.
PubMed 文献 · J Trauma Acute Care Surg · 2025-02-17
一句话结论在接受抗血小板治疗的TBI患者中,输注前后TEG-PM绝对值较高与死亡率降低、需神经外科干预减少和出血进展风险降低相关,但输注后TEG-PM的变化值及其他PHFA值均不能预测结局。

本研究为前瞻性随机对照试验的队列分析,纳入94例年龄18至89岁、有伤前抗血小板治疗史或因需血小板输注且被认为有神经外科干预风险的TBI患者,中位年龄76岁,43%为女性。检测输注前后血小板止血功能(PHFA),包括TEG-PM和VerifyNow,用逻辑回归评估其与30天全因死亡率、开颅手术需求和初始及随访Rotterdam评分的关系。30天死亡率为14%;VerifyNow阿司匹林检测能捕捉阿司匹林患者输注后血小板功能增加(Δ=65阿司匹林反应单位,p<0.001);TEG-PM参数在逻辑回归中可预测重要临床结局,但输注后PHFA变化值或多重比较校正后均无显著关联。结论认为TEG-PM输注前后绝对值较高与死亡减少、神经外科干预需求减少和出血进展风险降低相关,但变化值及其他PHFA值均不能预测结局。

要点

  • 在94例接受抗血小板治疗的TBI患者中,30天死亡率为14%,中位年龄76岁,43%为女性。
  • VerifyNow阿司匹林检测可捕捉阿司匹林患者血小板输注后血小板功能增加(显著正向Δ=65阿司匹林反应单位,p<0.001)。
  • TEG-PM参数在逻辑回归中可预测重要临床结局,但输注后PHFA变化值或多重比较校正后均未发现与临床结局的显著关联。
  • 结论认为,TEG-PM输注前后绝对值较高与死亡率降低、神经外科干预需求减少和出血进展风险降低相关;变化值及其他PHFA值均不能预测结局。

适用人群与场景

  • 年龄18至89岁、有伤前抗血小板治疗史或因需血小板输注、且被认为有神经外科干预风险的TBI患者。

研究设计与关键结果

  • 研究类型为前瞻性随机对照试验的队列分析,纳入94例TBI患者,43%为女性,中位年龄76岁。
  • 30天全因死亡率为14%。
  • VerifyNow阿司匹林检测能捕捉阿司匹林患者血小板输注后血小板功能增加(显著正向Δ=65阿司匹林反应单位,p<0.001)。
  • TEG-PM参数检测到输注后血小板功能改善,尽管变化的绝对值很小。
  • TEG-PM参数在逻辑回归中可预测重要临床结局,但输注后PHFA变化值或多重比较校正后均未发现与临床结局的显著关联。
  • 结论认为,TEG-PM输注前后绝对值较高与死亡率降低、神经外科干预需求减少和出血进展风险降低相关;变化值及其他PHFA值均不能预测结局。

证据类型、等级与局限

  • 证据类型:前瞻性随机对照试验的队列分析;证据等级:预后与流行病学,Level II。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论认为,TEG-PM输注前后绝对值较高与死亡率降低、神经外科干预需求减少和出血进展风险降低相关,但变化值及其他PHFA值均不能预测结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Traumatic brain injury (TBI) patients on antiplatelet therapy face higher mortality because of impaired platelet function, which may be treated by platelet transfusion. The value of testing platelet function in this cohort remains controversial. We aimed to evaluate the relationship between platelet function assays and outcomes in TBI patients on antiplatelet therapy receiving platelet transfusions. We hypothesized that the magnitude of change in platelet assay performance following a transfusion would predict meaningful clinical outcomes.

METHODS: A cohort of patients, aged 18 to 89 years, with a history of preinjury antiplatelet therapy or who required platelet transfusion, and who were deemed at risk for neurosurgical intervention, was selected from a prospective randomized controlled trial of platelet transfusion for TBI. Pre- and posttransfusion blood samples were drawn. Platelet hemostatic function assays (PHFAs) included thromboelastography with platelet mapping (TEG-PM) and VerifyNow. Logistic regression models assessed the association of temporal assay results with 30-day all-cause mortality, need for craniotomy, and initial and follow-up Rotterdam scores.

RESULTS: Data from 94 TBI patients (43% female) with a median age of 76 years were analyzed. The 30-day mortality rate was 14%. VerifyNow aspirin assay was able to capture increases in platelet function following a platelet transfusion in patients on aspirin (significant positive Δ = 65 aspirin response units, p < 0.001). Thromboelastography with platelet mapping parameters detected improved platelet function following transfusion, although the absolute value of changes was minimal. Thromboelastography with platelet mapping parameters predicted important clinical outcomes on logistic regression, although no significant associations with clinical outcomes were identified by the change in PHFA after transfusion or after adjusting for multiple comparisons.

CONCLUSION: Higher absolute pre- and posttransfusion values of TEG-PM were associated with decreased mortality, decreased need for neurosurgical intervention, and decreased risk of progression of hemorrhage in TBI patients taking antiplatelet agents, although neither the change in TEG-PM after transfusion nor any other PHFA value predicted outcomes.

LEVEL OF EVIDENCE: Prognostic and Epidemiological; Level II.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Alsaadi N, Younes R, Killinger JR, et al. Predictive value of platelet function assays in traumatic brain injury patients on antiplatelet therapy. J Trauma Acute Care Surg. 2025. PMID: 39956975. doi:10.1097/TA.0000000000004557

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。